%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
93 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-04-09T16:43:09Z
2024-03-28T04:34:01-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-28T04:34:01-07:00
application/pdf
Heather
2002-667.may
uuid:f757ac6e-1dd1-11b2-0a00-030927fd5800
uuid:f757ac71-1dd1-11b2-0a00-6a0000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
13 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
115 0 obj
[119 0 R]
endobj
116 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(3.)-875.1 (Schulz KF)79.7 (, Chalmers I, Hayes RJ, )54.8 (Altman DG. Empirical evidence)]TJ
1.675 -1.25 Td
(of bias. Dimensions of methodological quality associated with )Tj
0 -1.25 TD
[(estimates of treatment ef)17.7 (fects in controlled trials. JAMA)-220.2 (1995;)]TJ
0 Tc 0 Tw T*
(273:408-12.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Jadad )54.8 (AR, Rennie D. )17.7 (The randomized controlled trial gets a)]TJ
1.675 -1.25 Td
[(middle-aged checkup. JAMA)-220.2 (1998;279:319-20.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Kyriakidi M, Ioannidis JP)110.7 (. Design and quality considerations for)]TJ
1.675 -1.25 Td
[(randomized controlled trials in systemic sclerosis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;47:73-81.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (Hill CL, LaV)110.7 (alley MP)110.7 (, Felson DT)73.9 (. Secular changes in the quality of)]TJ
1.675 -1.25 Td
[(published randomized clinical trials in rheumatology)64.8 (. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2002;46:779-84.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Bland JM, )54.8 (Altman DG. Statistical methods for assessing agreement)]TJ
1.675 -1.25 Td
(between two methods of clinical measurement. Lancet 1986;)Tj
0 Tc 0 Tw T*
(1:307-10. )Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Moher D, Dulber)17.7 (g CS, )17.7 (W)79.9 (ells GA. Statistical power)39.7 (, sample size,)]TJ
1.675 -1.25 Td
(and their reporting in randomized controlled trials. JAMA)Tj
0 Tc 0 Tw T*
(1994;272:122-4.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Ioannidis JP)110.7 (, Lau J. Completeness of safety reporting in randomized)]TJ
1.675 -1.25 Td
[(trials: an evaluation of 7 medical areas. JAMA)-220.2 (2001;285:437-43.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Begg C, Cho M, Eastwood S, et al. Improving the quality of)]TJ
2.175 -1.25 Td
[(reporting of randomized controlled trials. )17.7 (The CONSOR)59.7 (T)]TJ
T*
[(statement. JAMA)-220.2 (1996;276:637-9.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Altman DG, Schulz KF)79.7 (, Moher D, et al. )17.7 (The revised CONSOR)59.7 (T)]TJ
2.1381 -1.25 Td
(statement for reporting randomized trials: explanation and )Tj
T*
[(elaboration. )54.8 (Ann Intern Med 2001;134:663-94.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Strand )17.7 (V)128.9 (, Gladman D, Isenber)17.7 (g D, Petri M, Smolen J, )17.7 (T)35 (ugwell P)110.7 (.)]TJ
2.175 -1.25 Td
[(Endpoints: consensus recommendations from OMERACT)-257.3 (IV)128.8 (.)]TJ
T*
[(Outcome Measures in Rheumatology)64.8 (. Lupus 2000;9:322-7.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Isenber)17.7 (g D, Ramsey-Goldman R. )54.8 (Assessing patients with lupus:)]TJ
2.175 -1.25 Td
(towards a drug responder index. Rheumatology Oxford.)Tj
0 Tc 0 Tw T*
(1999;38:1045-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (Easterbrook P)110.7 (, Berlin JA, Gopalan R, Matthews DR. Publication)]TJ
2.175 -1.25 Td
(bias in clinical research. Lancet 1991;337:867-72.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Ioannidis JP)110.7 (. Ef)17.7 (fect of the statistical significance of results on the)]TJ
2.175 -1.25 Td
[(time to completion and publication of randomized ef)17.7 (ficacy trials.)]TJ
0 Tc 0 Tw T*
[(JAMA)-220.1 (1998;279:281-6.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Balk EM, Bonis P)91.7 (AL, Moskowitz H, et al. Correlation of quality)]TJ
2.175 -1.25 Td
[(measures with estimates of treatment ef)17.7 (fect in meta-analyses of)]TJ
T*
[(randomized trials. JAMA)-220.2 (2002;287:2973-82.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Ioannidis JP)110.7 (, Lau J. Can quality of clinical trials and meta-analyses)]TJ
2.175 -1.25 Td
(be quantified? Lancet 1998;352:590-1. )Tj
-2.175 -1.25 Td
[(18.)-875.1 (Moher D, Pham B, Jones )54.8 (A, et al. Does quality of reports of)]TJ
2.175 -1.25 Td
[(randomised trials af)17.7 (fect estimates of intervention ef)17.7 (ficacy reported)]TJ
T*
(in meta-analyses? Lancet 1998;352:609-13.)Tj
30.825 55 Td
[(19.)-875.1 (Ioannidis JP)91.7 (A, Lau J. )17.7 (The impact of high risk patients on the results)]TJ
2.175 -1.25 Td
(of clinical trials. J Clin Epidemiol 1997;50:1089-98.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Fleming )17.7 (TR, DeMets DL. Monitoring of clinical trials: issues and)]TJ
2.175 -1.25 Td
[(recommendations. Control Clin )17.7 (T)35 (rials 1993;14:183-97.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Lan KK, Rosenber)17.7 (ger )17.7 (WF)79.7 (, Lachin JM. Use of spending functions)]TJ
2.175 -1.25 Td
(for occasional or continuous monitoring of data in clinical trials.)Tj
T*
(Stat Med 1993;12:2219-31.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Corzillius M, Bae SC. Methodological issues of corticosteroid use)]TJ
2.175 -1.25 Td
(in SLE clinical trials. Lupus 1999;8:692-7.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Austin HA)-220.2 (3rd, Klippel JH, Balow JE, et al. )17.7 (Therapy of lupus)]TJ
2.175 -1.25 Td
(nephritis. Controlled trial of prednisone and cytotoxic drugs. )Tj
0 Tc T*
(N Engl J Med 1986;314:614-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875.1 (Boumpas DT)73.9 (, )54.8 (Austin HA)-220.2 (3rd, )17.7 (V)110.8 (aughn EM, et al. Controlled trial of)]TJ
2.175 -1.25 Td
(pulse methylprednisolone versus two regimens of pulse )Tj
T*
(cyclophosphamide in severe lupus nephritis. Lancet 1992;)Tj
0 Tc 0 Tw T*
(340:741-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875.1 (Lewis EJ, Hunsicker LG, Lan SP)110.7 (, Rohde RD, Lachin JM. )54.8 (A)]TJ
2.175 -1.25 Td
(controlled trial of plasmapheresis therapy in severe lupus nephritis.)Tj
T*
(The Lupus Nephritis Collaborative Study Group. N Engl J Med)Tj
0 Tc 0 Tw T*
(1992;326:1373-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Y)110.8 (usuf S, Collins R, Peto R. )17.7 (Why do we need some lar)17.7 (ge, simple)]TJ
2.175 -1.25 Td
(randomized trials? Stat Med 1984;3:409-22.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality)]TJ
2.175 -1.25 Td
[(in systemic lupus erythematosus during a 5-year period. )54.8 (A)]TJ
T*
[(multicenter prospective study of 1,000 patients. European )17.7 (W)79.9 (orking)]TJ
T*
(Party on Systemic Lupus Erythematosus. Medicine 1999;)Tj
0 Tc 0 Tw T*
(78:167-75.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (W)79.9 (ard MM. Hospital experience and mortality in patients with)]TJ
2.175 -1.25 Td
[(systemic lupus erythematosus. )54.8 (Arthritis Rheum 1999;42:891-8.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Ioannidis JP)91.7 (A, Haidich )54.8 (A-B, Lau J. )54.8 (Any casualties in the clash of)]TJ
2.175 -1.25 Td
(randomised and observational evidence? BMJ 2001;322: 879-80.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Illei GG, )17.7 (T)69.9 (akada K, Parkin D, et al. Renal flares are common in)]TJ
2.175 -1.25 Td
(patients with severe proliferative lupus nephritis treated with pulse)Tj
T*
(immunosuppressive therapy: Long-term follow-up of a cohort of)Tj
T*
(145 patients participating in randomized controlled studies.)Tj
T*
(Arthritis Rheum 2002;46:995-1002.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson J. Evidence for the superiority of )]TJ
2.175 -1.25 Td
(immunosuppressive drugs and prednisone over prednisone alone in)Tj
T*
(lupus nephritis. Results of a pooled analysis. N Engl J Med)Tj
0 Tc 0 Tw T*
[(1984;31)36.9 (1:1528-33.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (Bansal )17.7 (VK, Beto JA. )17.7 (T)35 (reatment of lupus nephritis: a meta-analysis)]TJ
2.175 -1.25 Td
[(of clinical trials. )54.8 (Am J Kidney Dis 1997;29:193-9.)]TJ
-2.175 -1.25 Td
[(33.)-875.1 (Boumpas DT)73.9 (, Balow JE. Outcome criteria for lupus nephritis trials:)]TJ
0 Tc 2.175 -1.25 Td
[(a critical overview)64.9 (. Lupus 1998;7:622-9.)]TJ
ET
0 0 0 0 scn
420 777 137 -27 re
f*
BT
0 0 0 1 scn
/T1_1 1 Tf
-0.00011 Tc 0 Tw 20.37 0 0 21 460.9631 760.6089 Tm
(\002\003\003\002\004\005\005\006\004\005)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:5)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(984)Tj
ET
0 0 0 0 scn
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
49 0 obj
<>
endobj
41 0 obj
<>
endobj
39 0 obj
<>
endobj
80 0 obj
<>
endobj
98 0 obj
<>
endobj
42 0 obj
<>
endobj
72 0 obj
<>stream
HUiPSY~A1=5֥"*ݨ 2(M#% "$ *(`W=85Ŕs^5uLMUns9Uwq
qy{@P֠ea|AxIl
?C~+7Y`Ÿ